STOCK TITAN
  1. Home
  2. Sec-filings
  3. RPRX
  4. [Form 4] Royalty Pharma plc Insider Trading Activity

Royalty Pharma insider filing: 8,558-share RSU grant to Director Ho

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) – Form 4 insider transaction:

On 31 Jul 2025, director Carole Ho reported receiving 8,558 Class A ordinary shares through two restricted-stock-unit (RSU) grants issued under the 2020 Independent Director Equity Incentive Plan:

  • 2,752 RSUs as an initial equity award.
  • 5,806 RSUs as a pro-rated annual award.

Both tranches vest 100 % on the earlier of (i) one year from grant or (ii) the next annual shareholders’ meeting. The awards carry a cost basis of $0, reflect routine board compensation, and increase Ho’s direct ownership to 8,558 shares. No shares were sold, no derivatives were involved, and the filing references no Rule 10b5-1 trading plan. The disclosure is informational and does not affect Royalty Pharma’s fundamentals.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine RSU grant raises director’s stake; neutral fundamental impact, modest alignment signal.

The filing details standard compensation rather than an open-market purchase. Although insider share accumulation can signal confidence, RSUs granted at $0 sharply limit its informational value for valuation. The stake—8,558 shares—is immaterial relative to RPRX’s float and market cap, so market impact should be negligible. Investors may view the additional ownership as a minor governance positive, but it does not alter revenue, cash flow, or strategic outlook. I therefore classify the disclosure as not impactful to the investment thesis.

Insider Ho Carole
Role Director
Type Security Shares Price Value
Grant/Award Class A Ordinary Shares 2,752 $0.00 --
Grant/Award Class A Ordinary Shares 5,806 $0.00 --
Holdings After Transaction: Class A Ordinary Shares — 2,752 shares (Direct)
Footnotes (1)
  1. Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ho Carole
(Last) (First) (Middle)
C/O ROYALTY PHARMA PLC
110 E. 59TH STREET
(Street)
NEW YORK NY 10022
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Shares 07/31/2025 A 2,752(1) A $0 2,752 D
Class A Ordinary Shares 07/31/2025 A 5,806(2) A $0 8,558 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
2. Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
Remarks:
/s/ Sean Weisberg, as Attorney-in-Fact for Carole Ho 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Royalty Pharma (RPRX) shares did Carole Ho acquire?

The Form 4 shows a total of 8,558 Class A ordinary shares were granted via RSUs.

What was the transaction date for the RPRX insider filing?

Both RSU grants are dated 31 July 2025.

At what price were the RSUs granted to Carole Ho?

The awards were issued at a $0 cost basis, typical for director compensation.

When will the granted RSUs to Carole Ho vest?

Each tranche vests 100 % on the earlier of one year from grant or the next annual shareholders’ meeting.

Did the Form 4 report any share sales or derivative transactions?

No. The filing lists only RSU grants; no disposals or derivatives were reported.